Commentary|Videos|November 20, 2026

Younger, Fitter AML Populations May Not Need Intensive Chemotherapy

Amir T. Fathi, MD, explains which assumptions about frontline AML treatment are ready to be challenged in the field.

For decades, intensive induction chemotherapy has been the default for fit patients with newly diagnosed acute myeloid leukemia (AML). In the PARADIGM trial (NCT04801797), azacitidine (Vidaza) plus venetoclax (Venclexta) was associated with substantially less time in the hospital over the first 30 days (mean, 12.5 vs 27.3 days), no intensive care admissions compared with 10% with induction chemotherapy, and a higher rate of proceeding to transplant (60% vs 40%). Investigators cautioned that these findings should not be generalized to patients with core binding factor or FLT3-mutated disease, for whom induction chemotherapy remains the recommended approach.

Amir T. Fathi, MD, director of the leukemia program at the Mass General Brigham Cancer Institute and professor of medicine at Harvard Medical School, spoke with CancerNetwork® at the 44th Annual Chemotherapy Foundation Symposium (CFS®), hosted by Physicians’ Education Resource®, LLC, following his presentation titled “Challenging the Dogma in Frontline AML Management.” He described which long-held assumptions the field is most overdue to challenge and what he hopes attendees take away from his presentation.

Transcript:

CancerNetwork: Which long-held assumptions in frontline AML do you think the field is most overdue to challenge, whether that be intensive chemotherapy as the default for fit patients, fitness-based treatment assignment, or others?

Fathi: I think all those things. Most of the data we have been able to generate support the use of more gentle therapies for younger, fitter patients [who are] newly diagnosed with acute myeloid leukemia. But our data do not apply to all of these patients because there were certain molecular subtypes that we excluded from our clinical trial. Those include patients with FLT3 mutations, core binding factor leukemias, and many patients with NPM1 mutations. A large chunk of favorable-risk patients, and some intermediate-risk patients, were excluded.

That doesn’t mean those patients wouldn’t potentially be appropriate if they were fit for more gentle therapy; it’s just that studies that enroll those patients need to be done with appropriate targeted therapies incorporated. But overall, I do think the field is moving toward more gentle therapy, and perhaps in time to oral therapies for patients with AML, which I think is a welcome development.

What do you hope those in attendance take away from your presentation?

I hope it was educational and informative. I hope people listened and understood that the field of AML is hopefully changing and evolving, and that there are patients who are younger and fitter who may not need to be exposed to intensive chemotherapy and may get to where they need to be, which is oftentimes transplant, even with more gentle treatments; spending more time out of the hospital; and experiencing less toxicity. I think that’s all very promising.

Reference

Fathi AT, Perl AE, Fell GG, et al. Azacitidine–venetoclax or induction chemotherapy for acute myeloid leukemia. N Engl J Med. 2026;395(9):845-858. doi:10.1056/NEJMoa2602804


Related to this article